• Something wrong with this record ?

Acute Procedural Results of Pulsed Field Cryoablation for Persistent Atrial Fibrillation: Multicenter First-in-Human PARALELL Trial

V. Essebag, L. Boersma, J. Petru, MM. Gallagher, VY. Reddy, T. De Potter, P. Derejko, P. Neuzil, I. Grigorov, A. Verma

. 2025 ; 36 (6) : 1411-1415. [pub] 20250416

Language English Country United States

Document type Journal Article, Multicenter Study, Clinical Trial

Persistent link   https://www.medvik.cz/link/bmc25015481

Grant support
This study was supported by the Fonds de Recherche du Québec-Santé and Adagio Medical.

INTRODUCTION: Pulsed Field Cryoablation (PFCA) is a dual-energy cardiac ablation modality consisting of short-duration ultra-low temperature cryoablation (ULTC) followed immediately by pulsed field ablation (PFA) delivered from the same catheter. It is hypothesized that PFCA may improve contact stability during PFA, while maintaining lesion depth and effectiveness of ULTC. METHODS: PARALELL is a first-in-human multicenter study evaluating safety and effectiveness of a novel PFCA catheter and system in patients with persistent atrial fibrillation (PsAF) using the combination of pulmonary vein (PVI) and posterior wall (PWI) isolation. RESULTS: Sixty-six patients were ablated at six sites. One groin hematoma and one intubation-related hospitalization were the only serious procedure- or device-related adverse events recorded in the study. Per protocol, acute effectiveness was evaluated in 46 patients, including 31 patients with post-hoc analysis of cryogenic energy per lesion. After an average of 21.1 ± 9.3 lesions per patient the rates of PVI and PWI were 95.7% (176/184) and 97.7% (42/43), respectively. The average cryogenic energy per patient was highly predictive of acute isolation success with ROC AUC = 0.944% and 100% rates of both PVI and PWI in 24 patients in the optimal energy cohort. Grade I microbubbles and faint muscle contractions were detected in 1.1% and 0.5% of ablations, respectively. CONCLUSION: This initial multi-center experience suggests that PFCA can be efficiently performed for PVI and PWI using a single versatile catheter system, with high acute success and good early safety profile. The evaluation of the chronic 12-month effectiveness of PFCA is ongoing.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015481
003      
CZ-PrNML
005      
20250731091018.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jce.16680 $2 doi
035    __
$a (PubMed)40237369
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Essebag, Vidal $u McGill University Health Centre, Montreal, Quebec, Canada $1 https://orcid.org/0000000301075197
245    10
$a Acute Procedural Results of Pulsed Field Cryoablation for Persistent Atrial Fibrillation: Multicenter First-in-Human PARALELL Trial / $c V. Essebag, L. Boersma, J. Petru, MM. Gallagher, VY. Reddy, T. De Potter, P. Derejko, P. Neuzil, I. Grigorov, A. Verma
520    9_
$a INTRODUCTION: Pulsed Field Cryoablation (PFCA) is a dual-energy cardiac ablation modality consisting of short-duration ultra-low temperature cryoablation (ULTC) followed immediately by pulsed field ablation (PFA) delivered from the same catheter. It is hypothesized that PFCA may improve contact stability during PFA, while maintaining lesion depth and effectiveness of ULTC. METHODS: PARALELL is a first-in-human multicenter study evaluating safety and effectiveness of a novel PFCA catheter and system in patients with persistent atrial fibrillation (PsAF) using the combination of pulmonary vein (PVI) and posterior wall (PWI) isolation. RESULTS: Sixty-six patients were ablated at six sites. One groin hematoma and one intubation-related hospitalization were the only serious procedure- or device-related adverse events recorded in the study. Per protocol, acute effectiveness was evaluated in 46 patients, including 31 patients with post-hoc analysis of cryogenic energy per lesion. After an average of 21.1 ± 9.3 lesions per patient the rates of PVI and PWI were 95.7% (176/184) and 97.7% (42/43), respectively. The average cryogenic energy per patient was highly predictive of acute isolation success with ROC AUC = 0.944% and 100% rates of both PVI and PWI in 24 patients in the optimal energy cohort. Grade I microbubbles and faint muscle contractions were detected in 1.1% and 0.5% of ablations, respectively. CONCLUSION: This initial multi-center experience suggests that PFCA can be efficiently performed for PVI and PWI using a single versatile catheter system, with high acute success and good early safety profile. The evaluation of the chronic 12-month effectiveness of PFCA is ongoing.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x chirurgie $x patofyziologie $x diagnóza $7 D001281
650    12
$a kryochirurgie $x škodlivé účinky $x přístrojové vybavení $x metody $7 D003452
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a senioři $7 D000368
650    12
$a venae pulmonales $x chirurgie $x patofyziologie $7 D011667
650    _2
$a časové faktory $7 D013997
650    _2
$a akční potenciály $7 D000200
650    _2
$a srdeční frekvence $7 D006339
650    _2
$a srdeční katétry $7 D062906
650    _2
$a rizikové faktory $7 D012307
650    _2
$a design vybavení $7 D004867
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky $7 D016430
700    1_
$a Boersma, Lucas $u St. Antonius Hospital, Nieuwegein, Utrecht, the Netherlands $u Amsterdam UMC, Amsterdam, North Holland, the Netherlands
700    1_
$a Petru, Jan $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Gallagher, Mark M $u St George's University Hospitals NHS Foundation Trust, London, UK
700    1_
$a Reddy, Vivek Y $u Na Homolce Hospital, Prague, Czech Republic $u Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, New York, USA $1 https://orcid.org/0000000256384993
700    1_
$a De Potter, Tom $u Cardiovascular Center, OLV Hospital, Aalst, East Flanders, Belgium
700    1_
$a Derejko, Pawel $u Medicover Hospital, Warsaw, Masovian Voivodeship, Poland $1 https://orcid.org/0000000333171837
700    1_
$a Neuzil, Petr $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Grigorov, Ilya $u Adagio Medical Inc., Laguna Hills, California, USA
700    1_
$a Verma, Atul $u McGill University Health Centre, Montreal, Quebec, Canada
773    0_
$w MED00002569 $t Journal of cardiovascular electrophysiology $x 1540-8167 $g Roč. 36, č. 6 (2025), s. 1411-1415
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40237369 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091013 $b ABA008
999    __
$a ok $b bmc $g 2366365 $s 1252606
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 36 $c 6 $d 1411-1415 $e 20250416 $i 1540-8167 $m Journal of cardiovascular electrophysiology $n J Cardiovasc Electrophysiol $x MED00002569
GRA    __
$p This study was supported by the Fonds de Recherche du Québec-Santé and Adagio Medical.
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options